PURE Bioscience, Inc.
PURE
$0.08
$0.000.60%
OTC PK
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.55% | 27.34% | 61.18% | 11.34% | 19.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.55% | 27.34% | 61.18% | 11.34% | 19.94% |
| Cost of Revenue | 25.61% | 11.69% | 48.74% | 13.66% | 10.07% |
| Gross Profit | 4.85% | 38.46% | 70.18% | 9.69% | 28.25% |
| SG&A Expenses | -2.76% | -15.66% | -13.49% | -22.24% | -18.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.99% | -8.11% | -1.17% | -14.55% | -13.49% |
| Operating Income | 5.79% | 39.55% | 47.42% | 28.52% | 24.79% |
| Income Before Tax | 1.63% | 32.66% | 56.08% | 32.32% | 20.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.63% | 32.66% | 56.08% | 32.32% | 20.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.63% | 32.66% | 56.08% | 32.32% | 20.36% |
| EBIT | 5.79% | 39.55% | 47.42% | 28.52% | 24.79% |
| EBITDA | 5.87% | 35.93% | 44.09% | 25.35% | 21.84% |
| EPS Basic | 1.41% | 33.87% | 55.88% | 32.47% | 21.11% |
| Normalized Basic EPS | 2.22% | 31.58% | 51.28% | 33.33% | 19.64% |
| EPS Diluted | 1.41% | 33.87% | 55.88% | 32.47% | 21.11% |
| Normalized Diluted EPS | 2.22% | 31.58% | 51.28% | 33.33% | 19.64% |
| Average Basic Shares Outstanding | 0.03% | 0.03% | 0.02% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.03% | 0.03% | 0.02% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |